Amgen gets European approval for biosimilar of Humira
Thousand Oaks-based Amgen has announced that the European Commission has granted marketing authorization for Amgevita, a drug that treats inflammatory diseases, including moderate-to-severe rheumatoid arthritis. The Amgen biosimilar will compete with AbbVie’s blockbuster drug Humira. “The approval of our first biosimilar by the European Commission is a major milestone not just for Amgen as a company, but for the millions Read More →
Read More →Embracing trade does not make you a traitor
By Gerhard Apfelthaler On a recent trip to Iran, I couldn’t help but notice the difference in the public narrative regarding the lifting of the sanctions against Iran. While many people in the United States — at least according to mainstream media — seem to think that they got the short end of the stick, Read More →
Read More →Dubroff: Appeal of populism falls short of reality
“You say you want a revolution Well, you know, we all want to change the world” — John Lennon My verdict on the so-called “Brexit” vote is that in a globalized world dominated by central bankers, it is far more profitable to sing about a revolution than to actually foment one. Less than a week Read More →
Read More →Power-One predicts European solar revival in Q2
Signs of a resurgence in its European market prompted Power-One to project better-than-expected second-quarter profits on May 3 even as it said that first-quarter income dropped 84.1 percent to $4.9 million, or 3 cents per diluted share. Net sales were up 8.3 percent to $225.8 million. The company’s renewable energy division contributed $149 million to Read More →
Read More →
Power-One looks to Asia for growth
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Power-One docks outlook on Eurozone austerity
Power products company Power-One slashed its third-quarter outlook Oct. 11, causing stocks to sink 3.8 percent in after-hours trading. The Camarillo-based firm cut its outlook for third-quarter sales to the $240 million to $245 million range, down from its previous outlook of $265 million to $280 million. It said power conversion revenue was down about Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
